FindTrial
Sign In

Perioperative drug use in oral cancer recurrence

Perioperative drug exposure in oral cancer patients and its influence on oncological outcome: A Retrospective Study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/10/075121
Enrollment
364
Registered
2024-10-11
Start date
Unknown
Completion date
Unknown
Last updated
2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C00-D49- Neoplasms

Interventions

Intervention1: NIL: NIL Control Intervention1: NIL: NIL

Sponsors

Kasturba Medical College Manipal
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients diagnosed with oral cancer and undergone surgery between January 2018 and June 2021 Patients diagnosed with oral cancer and confirmed histopathologicaly All cases of Stage 2 and Stage 3 Patients have been there for follow up for at least 3 year at Kasturba Hospital Manipal

Exclusion criteria

Exclusion criteria: All cases of Stage 4 oral cancer Patients with incomplete medical records or insufficient follow-up data

Design outcomes

Primary

MeasureTime frame
the proportion of patients who experienced recurrence of oral cancer within a timeframe of at least 3 years Evaluate the pattern of use and association of drugs (peri operative) used in oral cancer management on time to recurrence and overall survival Timepoint: Every Year for 3 Years or Till Recurrence—

Secondary

MeasureTime frame
Influence of treatment modalities (surgery, radiation therapy, chemotherapy) on both overall survival & time to recurrenceTimepoint: Every Year for 3 Years or Till Recurrence—

Countries

India

Contacts

Public ContactYashwin Bhagchandani

Kasturba Medical College Manipal

shalini.adiga@manipal.edu9448521328

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026